Zhejiang Hisoar Stock Hits Day High with Strong Intraday Performance

Zhejiang Hisoar Pharmaceutical Co., Ltd. has experienced a notable uptick in its stock performance, gaining 3.46% on March 27, 2026. The stock reached an intraday high of CNY 7.28, reflecting a significant moment in its trading activity. In terms of performance metrics, the company has shown a 6.54% increase over the past week, contrasting with a decline of 1.09% in the China Shanghai Composite index. Over the past year, Zhejiang Hisoar has outperformed the broader market, with a remarkable 37.36% increase compared to the composite's 16.01%. However, the company has faced challenges in longer-term growth, with a decline in net sales at an annual rate of 5.79% over the last five years. Despite the recent gains, the company’s financial health raises concerns, highlighted by a low Return on Capital Employed (ROCE) of 2.16% and a negative return on equity of -2.17%. With a market capitalization of CNY 11,906 million, Zhejiang Hisoar remains a significant player in the pharmaceuticals and biotechnology sector, though its financial metrics suggest a need for strategic reassessment.